We have read the recent letter by Honore et al. \[[@CR1]\] about our findings published in this journal regarding the influence of continuous renal replacement therapy (CRRT) on the pharmacokinetics of ceftolozane-tazobactam (C/T) \[[@CR2]\]. In our report, we decided to administer a 3 g/iv dose every 8 h taking into account two previous studies referenced in our paper \[[@CR2]\] and another one which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18--17.39, *p* = 0.02) when C/T is administered at 1.5 g every 8 h \[[@CR3]\].

As Honore et al. explain in their paper, the C/T eliminitation was assumed by hemodiafiltration and the adsorption was not assessed \[[@CR1]\]. However, there is a misunderstanding in this letter \[[@CR1]\], because we used a polysulphone membrane (Fresenius, Germany) instead of an acrylonitrile 69 Multiflow (AN-69-M). In contrast to highly adsorptive membranes (HAM; e.g., AN69 surface-treated, AN69-ST), the antibiotic adsorption with polysulphone ones is negligible, which facilitates antibiotic adaptation during CRRT \[[@CR4]\].

Our data should not be extrapolated to other clinical scenarios, as noted by Honore et al. \[[@CR1]\]. In our report, ceftolozane and tazobactam plasma concentrations remained above the minimal inhibitory concentration (MIC), for MICs of up to 8 μg/mL, but we estimated that the administration of standard doses of 1 g/0.5 g, even with polysulphone membranes, could compromise the effectiveness of C/T for not reaching adequate tazobactam concentrations. Thus, the use of HAM would represent a real risk factor of clinical failure when a C/T dose of 1.5 g every 8 h is administered, especially in multidrug-resistant infections \[[@CR3]\]. Therefore, we agree with Honore et al. \[[@CR1]\] that therapeutic drug monitoring (TDM) is critical when using C/T for patients receiving CRRT, especially when MICs of bacteria like multidrug-resistant (MDR) *Pseudomonas aeruginosa* are considered very high. However, the recommendation of continuous (over 24 h) vs extended (over 2 to 4 h) or intermittent (over 30 to 60 min) infusion of beta-lactams is still under debate \[[@CR5]\].
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